{"organizations": [], "uuid": "e45d89b7400b4d4c39cbab0a45969ce4a178b6fb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/aurka-pharma-ma-lilly/eli-lilly-to-buy-cancer-drug-developer-aurka-pharma-idUSL3N1SL4PI", "country": "US", "domain_rank": 408, "title": "Eli Lilly to buy cancer drug developer AurKa Pharma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-14T14:52:00.000+03:00", "replies_count": 0, "uuid": "e45d89b7400b4d4c39cbab0a45969ce4a178b6fb"}, "author": "", "url": "https://www.reuters.com/article/aurka-pharma-ma-lilly/eli-lilly-to-buy-cancer-drug-developer-aurka-pharma-idUSL3N1SL4PI", "ord_in_thread": 0, "title": "Eli Lilly to buy cancer drug developer AurKa Pharma", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "arun koyyur", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "eli lilly", "sentiment": "negative"}, {"name": "aurka pharma reuters", "sentiment": "negative"}, {"name": "eli lilly and co", "sentiment": "none"}, {"name": "aurka pharma inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "aurka pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 14, 2018 / 11:53 AM / in 25 minutes Eli Lilly to buy cancer drug developer AurKa Pharma Reuters Staff 1 Min Read\nMay 14 (Reuters) - Drugmaker Eli Lilly and Co said on Monday it would buy AurKa Pharma Inc to get access to the privately-held companyâ€™s experimental cancer treatment for solid tumors.\nAurKa Pharma shareholders will get an upfront payment of $110 million and will be eligible to receive up to $465 million in regulatory and sales milestones, Eli Lilly said in a statement. Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur", "external_links": [], "published": "2018-05-14T14:52:00.000+03:00", "crawled": "2018-05-14T15:20:07.003+03:00", "highlightTitle": ""}